

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/163485/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Maillard, Jean-Yves and Pascoe, Michael 2024. Disinfectants and antiseptics: mechanisms of action and resistance. *Nature Reviews Microbiology* 22 , pp. 4-17. 10.1038/s41579-023-00958-3

Publishers page: <http://dx.doi.org/10.1038/s41579-023-00958-3>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 **Disinfectants and antiseptics: mechanisms of action and resistance**

2
3 Jean-Yves Maillard^{1*}, Michael Pascoe¹

4
5 ¹School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Wales, UK

6
7 *e-mail: maillardj@cardiff.ac.uk

8 9 10 **ABSTRACT**

11 Chemical biocides are used for infection prevention and control in healthcare, targeted home
12 hygiene, or controlling microbial contamination for various industrial processes including but
13 not limited to food, water and petroleum. However, their use has substantially increased since
14 the implementation of programmes to control outbreaks of methicillin resistant *Staphylococcus*
15 *aureus* (MRSA), *Clostridioides difficile* and SARS-CoV-2. Biocides interact with multiple
16 targets on the bacterial cells. The number of targets affected, and the severity of damage will
17 result in an irreversible bactericidal effect or a reversible bacteriostatic one. Most biocides
18 primarily target the cytoplasmic membrane and enzymes, although the specific bactericidal
19 mechanisms vary among different biocide chemistries. Inappropriate usage or low
20 concentrations of a biocide may act as a stressor whilst not killing bacterial pathogens,
21 potentially leading to antimicrobial resistance. Biocides can also promote the transfer of
22 antimicrobial resistance genes. In this Review, we explore our current understanding of the
23 mechanisms of action of biocides, the bacterial resistance mechanisms encompassing both
24 intrinsic and acquired resistance, and the influence of bacterial biofilms on resistance. We also
25 consider the impact of bacteria that survive biocide exposure in environmental and clinical
26 contexts.

27 28 **Table of contents blurb (~50 words max.)**

29 In this Review, Maillard and Pascoe examine the mechanisms of action of biocides, as well
30 as the bacterial intrinsic and acquired resistance to these biocides and its implications in the
31 environmental and clinical settings.

37 [H1] Introduction

38 Antimicrobial biocides, also known as microbicides, are distinct from chemotherapeutic
39 antibiotics and they are used in a wide range of applications including disinfection, antiseptis
40 and preservation. Whilst some may be used for either application, the terms disinfectant and
41 antiseptic respectively refer to biocides used on non-living surfaces and living tissues (for
42 example, the skin). The use of biocides has been documented for centuries¹, well before the
43 Germ Theory of Diseases by Louis Pasteur² and Koch's postulates³. The work of Ignaz
44 Semmelweis represents an important moment in the modern use of disinfection and
45 antiseptis, as it introduced chlorinated lime water for hand disinfection⁴, leading to a reduction
46 in the incidence of puerperal fever following births. Most of contemporary biocides were
47 introduced during the 20th century¹, and with improved public awareness about infections and
48 "superbugs", it is now difficult to find consumer hygiene products lacking biocides and claims
49 of antimicrobial activity^{5,6}.

50 The COVID-19 pandemic contributed to an escalation of surface, air and skin disinfection. The
51 persistence of SARS-CoV-2 on surfaces, at least for a few hours, not only highlighted the need
52 to improve surface and hand hygiene compliance, but also provided a reason for disinfectant
53 manufacturers to provide longer-lasting antimicrobial protection of surfaces. Footage of
54 disinfectants being sprayed in streets during the pandemic reflects this increase in public
55 awareness. Enhanced control measures during the pandemic were not only limited to the
56 healthcare setting, but also affected domiciliary, transportation, manufacturing, and corporate
57 sectors; global demand for biocides was estimated to increase 600% during this period⁷.
58 Increasing product usage for disinfection and antiseptis means increasing bacterial exposure
59 to biocides.

60 Many biocide chemistries have been used in disinfectants and antiseptics over the years¹.
61 The purpose of disinfectants and antiseptics is to kill target microorganisms, effectively
62 reducing their number on skin, surfaces, materials or in water. Unlike chemotherapeutic
63 antibiotics, biocides at their in-use concentration exert bactericidal activity by affecting multiple
64 targets on the bacterial cell. Interactions between biocides and bacterial targets depend on
65 the chemical nature of the biocide, but also on other several factors, some pertinent to
66 application⁵. The poor understanding of manufacturers regarding the different chemistries,
67 including factors that affect efficacy, and inappropriate usage or/and misuse of products (such
68 as incorrect dilution or insufficient contact time) can lead to bacterial survival, potential
69 selection or adaptation. In turn, this may result in bacterial resistance and cross-resistance to
70 unrelated compounds including antibiotics. Decreased bacterial susceptibility to biocides,
71 often referred to as resistance, has been reported since the 1950s and has now been reported
72 for all major types of biocides⁸. In contrast to chemotherapeutic antibiotics, where clinical
73 breakpoints can be used to clearly define 'resistance', the definition of resistance for biocides

74 is more open to interpretation. Definitions are linked to the protocol used to measure a
75 bacterial change in antimicrobial susceptibility profiles, though these protocols are not
76 standardised⁵. In this Review, the term biocide resistance is used holistically and does not
77 distinguish between decreased susceptibility (a change in susceptibility profile measured by
78 bacteriostasis or growth inhibition), resistance (measured by bactericidal protocols) or
79 tolerance (ability of bacteria to survive a biocide at an in-use concentration).

80 Bacteria can be naturally tolerant (intrinsically resistant) to a biocide based on innate
81 physiological factors, which may contribute toward an ability to survive — and in some cases
82 thrive — in solutions containing biocides. Some reported outbreaks originated from
83 contamination of specific disinfectant or antiseptic products by intrinsically resistant bacteria;
84 for example, contamination of chlorhexidine solution with *Burkholderia cepacia*⁹,
85 benzalkonium chloride solutions with *Serratia marcescens*¹⁰, or alcohol solutions with *Bacillus*
86 *cereus* spores¹¹. Bacteria can also acquire mechanisms leading to resistance through gene
87 exchange or/and genetic mutations (acquired resistance)¹². Investigations concerning
88 processes where biocides are routinely used, such as endoscope reprocessing, have provided
89 remarkable insights into environmental isolates that are not only resistant to the in-use
90 concentration of high-level disinfectants used in the process, but also to unrelated
91 biocides^{13,14}. The clinical implications of these findings, however, remains poorly established
92 and the mechanism of resistance for some isolates remain uncertain¹⁵.

93 Whilst the use of biocides is an essential cornerstone for infection control and general hygiene,
94 their overuse and misuse may represent a driver for the emergence of antimicrobial resistance
95 (AMR) in bacteria^{5,6}. The topic of biocide resistance was comprehensively discussed in a
96 series of reviews across the 1990s and early 2000s.¹⁶⁻¹⁸ More recent reviews on the subject
97 have focused on specific issues posed by particular biocides¹⁹, resistance mechanisms²⁰,
98 areas of use²¹, or provide limited information on the impact on AMR emergence²².

99 In this Review, we provide a holistic introduction to the different types of biocide chemistries
100 used in disinfectant and antiseptic products, their applications, mechanisms of action and
101 factors that contribute towards antimicrobial efficacy. We discuss the mechanisms of bacterial
102 resistance to biocides and methodologies used to determine resistance, to understand the
103 practical and clinical implications of recent studies in this area. Finally, we explore existing
104 evidence on the role of biocides in driving antimicrobial resistance development through
105 shared mechanisms of resistance.

106

107 **[H1] Types of biocides and biocide-bacteria interactions**

108

109 *[H2] Main types of biocides commonly used in disinfectant and antiseptic products*

110 Biocides are chemically diverse, with over 900 chemistries available in the European market.
111 Given the importance of establishing efficacy and safety, many markets have enacted specific
112 legislation to regulate their sale. In the European Union, biocides are regulated by the
113 European Chemicals Agency ([ECHA](#)) under the [Biocidal Products Regulations \(BPR\)](#) and are
114 differentiated into 22 product types depending on their intended application; in the United
115 Kingdom, the legislation is currently aligned with the European Union BPR, with the Health
116 and Safety Executive serving as the enforcing authority. Similar regulations are also in place
117 in other countries worldwide, for example, the United States (Federal Insecticide, Fungicide,
118 and Rodenticide Act), China (Regulation on the Administration of Pesticides) and Japan
119 (Pharmaceutical and Medical Devices Act).

120 The type of biocide chemistry used in formulations depends on their application (Table 1).
121 Generally, the impact of formulated biocides (biocide chemistries and excipients) on efficacy
122 is not as well reported as the efficacy of unformulated biocides. Yet, when formulated biocides
123 are studied, for example formulated benzalkonium chloride, their bactericidal efficacy is
124 improved and emerging antibiotic-resistance decreased¹⁹. Less-reactive, surface-compatible
125 or less toxic biocides such as quaternary ammonium compounds (QAC), biguanides, alcohols
126 and phenolics, may be used on skin and are extensively used on non-porous surfaces in
127 healthcare, food, transport, corporate and domiciliary industries²³.

128 Because of their wide range of applications, some biocides will enter the environment and
129 impact antimicrobial resistance²⁴. In this Review we will discuss some examples, but we will
130 not consider their breakdown products or reaction by-products.

131 More reactive biocides, such as oxidisers (for example, chlorine or peroxygen-based
132 disinfectants) and alkylating agents (for example, glutaraldehyde) are more efficacious and
133 are used in applications where target microorganisms are considered less susceptible to
134 biocides (FIG. 1), as in the case of bacterial endospores that require high-level disinfection
135 (Supplementary Box 1)²⁵. This comes at the cost of increased toxicity, incompatibility with
136 some surface types and reduced residual activity. When appropriately formulated, these
137 biocides are widely applied to disinfect non-living (abiotic) surfaces and liquids, such as
138 drinking water. Product formulation is critical not only for efficacy but also to improve material
139 compatibility and decrease toxicity²⁶. The reactivity of biocides refers to their interaction with
140 microbial targets, whether there is a strong interaction with the target through chemical or ionic
141 binding or a weak physical interaction with lipophilic components of the membrane²⁷.

142 [H2] *Mechanisms of biocide action*

143 At their in-use concentration, biocides exert their bactericidal action by interacting with multiple
144 target sites (FIG. 2). This is in contrast to antibiotics, which acts at specific target sites^{23,27}.
145 The number of targets that are affected by the biocide and the severity of the damage imparted
146 to these targets results in bacteriostatic or bactericidal effects (FIG. 2)⁸. It is challenging to
147 determine the exact mechanisms of action due to the non-specific damage caused by
148 biocides. However, an understanding of the underlying chemistry can offer some insight
149 (Table 1). Microbial inactivation by biocides is complex and can be understood by using
150 multiple approaches. These include analysing the effects of biocides on membrane integrity
151 of live cells or vesicles and liposomes through the use of microscopy, the uptake of substrates
152 (for example, fluorescent dyes or particles), and the leakage of cellular components (for
153 example, potassium, ATP and nucleotides or DNA)²⁸⁻³⁰. Additionally, the effects on cellular
154 macromolecules can be evaluated by examining DNA integrity, enzyme activity, lipid or protein
155 modification³¹. Understanding the genotypic and phenotypic determinants that contribute to
156 susceptibility, particularly in the case of sporicides^{32,33}, is crucial. Computational modelling³⁴
157 and changes in metabolism and gene expression, typically following sub-lethal exposure^{35,36}
158 are also important. Except for the last example, where viability of the treated population must
159 be maintained, these studies typically use biocides at their in-use concentration; this contrasts
160 with studies concerning antibiotic mechanisms of action. As a rule, biocides must interact with
161 bacteria and reach their target sites in sufficient quantities to exert biocidal effect. For example,
162 the outer membrane of some Gram-negative species can provide intrinsic resistance to
163 quaternary ammonium compounds, by acting as a barrier that prevents interaction with the
164 cytoplasmic membrane. This will be discussed further in following sections. The initial
165 interaction of a biocide with the target bacterial cell is an important determinant of efficacy and
166 can be measured with uptake isotherms³⁷, which provide information on the nature and
167 strength of the interaction between a biocide and the microorganism³⁸.

168 The general mechanisms of action of biocides can be divided into different groups. Alkylating
169 agents (for example, aldehydes and ethylene oxide) act via cross-linking hydroxyl, amino,
170 carboxyl and sulfhydryl groups, impacting on enzyme function and nucleic acid structure,
171 resulting in microbiocidal effects. The extent of crosslinking ability depends on the alkylating
172 agents and does not necessarily impact on efficacy, although this will affect penetration inside
173 the cells. For example, glutaraldehyde interacts with the outer layer of the bacterial cells due
174 to its extensive crosslinking ability, whilst ortho-phthalaldehyde, ethylene oxide or formaldehyde
175 penetrate deeper within the cells and can impair nucleic acid and cytoplasmic enzyme
176 functions.

177 Another group is constituted by oxidising agents such as chlorine, iodine and peroxygens that
178 oxidise various chemical groups (amino, sulfhydryl, thiol) associated with lipids, proteins and

179 nucleic acids, thus disrupting major cytoplasmic membrane function, enzyme function and
180 DNA synthesis. Chlorine- and iodine-based compounds and peracetic acid have been
181 associated with membrane damage presumably through protein oxidation. The bactericidal
182 efficacy of hydrogen peroxide, however, is likely caused by nucleic acid damage rather than
183 lipid and protein oxidation, although hydrogen peroxide has been shown to interfere with
184 ribosomes preventing protein synthesis. Membrane active agents are very diverse and exert
185 their bactericidal activity through physical damage to the membrane or loss of membrane
186 function. Phenols, quaternary ammonium compounds (QAC) and biguanides will cause
187 potassium leakage, an early indicator of membrane integrity, followed with a change in pH
188 and cytoplasmic enzyme function. Hexachlorophene can inhibit metabolic activity by
189 interfering with the electron transport chain, whereas organic acids and their esters can impact
190 membrane potential, which affects cells proton motive force, resulting in the disruption of
191 active transport and oxidative phosphorylation. Polymeric biguanides such as
192 polyhexamethylene biguanide (PHMB) are also membrane active and interact with the
193 lipopolysaccharide in the outer membrane of Gram-negative bacteria, promoting self-
194 penetration and inducing phospholipids phase separation in the cytoplasmic membrane. The
195 fine interaction of QAC with the membrane depends on the QAC chemistry.

196 The bactericidal activity of alcohols is probably linked to denaturation of essential membrane
197 proteins, affecting membrane function, as well as cytoplasmic enzymatic functions. The loss
198 of membrane integrity and penetration of some biocides (biguanides, phenolics) into the cell
199 leads to cytoplasm coagulation and further loss of enzymatic functions.

200 At low concentration, some biocides can exhibit specific interactions with the bacterial cell. At
201 a low concentration, o-phenylphenol may interfere with cell wall peptidoglycan synthesis, and
202 triclosan interferes with enoyl acyl reductase, an enzyme involved in fatty acid synthesis and
203 lipid metabolism³⁹.

204 The initial interaction of a biocide with a bacterial cell is reversible, triggering adaptation and
205 repair mechanisms and ultimately bacterial survival (FIG. 2). A prolonged interaction would
206 result in severe damage to the bacterial cytoplasmic membrane leading to an irreversible
207 effect and eventually bacterial death⁸. Metabolically inactive bacteria or bacteria with reduced
208 metabolic activity are generally less susceptible to biocides^{40,41}.

209 The efficacy of a biocidal product can be influenced by several factors. Some of these factors
210 are inherent to the product, such as its concentration, pH, formulation excipients. Others are
211 related to the application of the product, such as the duration of contact, soiling, and the type
212 of surfaces. There are also factors that are inherent to the microorganisms being targeted
213 (Table 2). Concentration is arguably the most important, as it determines the extent and
214 severity of damage imparted to the bacterial cell^{42,43}.

215

216 [H1] Bacterial resistance to biocides

217

218 [H2] Intrinsic resistance

219 The ability to survive biocide exposure depends on the type of microorganism (FIG. 1) and
220 their intrinsic physiological properties. Intrinsic mechanisms of vegetative bacteria, bacterial
221 endospores and biofilms (multicellular, sessile bacterial communities) may be considered
222 separately (FIG. 3).

223 Amongst vegetative bacteria, mycobacteria are considered the least susceptible to biocides
224 due to their lipid-rich outer layer of mycolic acids surrounding the cell⁴⁴. In Gram-negative
225 bacteria, the lipopolysaccharide (LPS) layer of the outer membrane, the cytoplasmic
226 membrane lipid composition, and the number, size and substrate specificity of porins may also
227 confer decreased susceptibility to biocides³⁷. The importance of the outer membrane in
228 reducing biocide susceptibility can be best exemplified by the use of
229 ethylenediaminetetraacetic acid (EDTA), a metal chelator that disrupts the LPS layer in Gram-
230 negative bacteria to enhance the performance of biocides (FIG. 2)⁴⁵.

231 Bacterial endospores provide the best evidence of biocide resistance derived from intrinsic
232 cell properties. Bacterial endospores are formed through a sporulation process to facilitate
233 survival under adverse conditions⁴⁶. The lack of susceptibility of endospores from the two main
234 spore forming bacterial genera *Bacillus* spp. and *Clostridium* spp. (including *Clostridioides*
235 *difficile*), have been well reported⁴⁷. The mechanisms of bacterial endospore resistance to
236 biocides have been previously described and can be divided broadly into permeability barriers
237 and nucleic acid protection (FIG. 3)⁴⁶.

238 The intrinsic responses to resistance described thus far are pertinent to individual bacterial
239 cells. However, bacteria in the environment are usually found within multicellular communities
240 (biofilms) which provide additional challenges to biocide efficacy. In addition to the commonly
241 described 'wet' biofilms, which are associated with moist environments, biofilms can develop
242 on environmental dry surfaces⁴⁸. These dry-surface biofilms are widespread on surfaces
243 within healthcare environments^{49,50}, and are highly resilient to surface disinfection⁵¹. Biofilms
244 exhibit decreased susceptibility to biocides through several biofilm-intrinsic mechanisms, of
245 which extracellular polymeric substances (EPS) and persister cells are the most
246 described^{15,40,41}. EPS consists of secreted nucleic acids, proteins, lipids and carbohydrates.
247 Alongside cellular debris, EPS forms a matrix that acts as a diffusion barrier whilst also
248 quenching the activity of biocides. EPS is the main factor affecting susceptibility of
249 *Pseudomonas aeruginosa* biofilms to peracetic acid and benzalkonium chloride, and its
250 removal through washing yields cells with comparable susceptibility to vegetative bacteria⁵².
251 Cell density and biofilm thickness increase with age, conferring increased protection against
252 biocide exposure^{53,54}. The efficiency of diffusion through a biofilm varies between biocides.

253 For example, peracetic acid reduces *P. aeruginosa* biofilm viability uniformly upon contact,
254 whilst benzalkonium chloride penetrates slowly and directionally⁵². The ability of a biocide to
255 penetrate a biofilm does not entirely explain the differences observed in anti-biofilm
256 performance⁵⁵ and the EPS does not fully account for biocide resistance¹⁵, exemplifying the
257 importance of other mechanisms.

258 Persister cells are characterised by a substantially decreased growth rate and metabolic
259 activity, including protein synthesis⁵⁶. The EPS surrounding persister cells does not solely
260 explain their resistance to biocides, as EPS-free cells retain increased tolerance⁴⁰. Induction
261 of persister phenotypes is driven by stress-induced signals⁵⁶ and is partly mediated by the
262 SOS response, which also confers protection against DNA damage⁵⁷.

263

264 [H2] Acquired resistance

265 In contrast to intrinsic resistance, acquired resistance involves the acquisition of new
266 properties following gene transfer or mutation. Since biocides interact with multiple targets in
267 bacteria (FIG. 2), reports of mutation(s) responsible for bacterial resistance to in-use
268 concentrations of a biocide are rare. However, the impact of mutations on decreasing
269 susceptibility to biocides, as measured by minimum inhibitory concentration (MIC), is more
270 widely reported⁵⁸. For example, a recent report showed that repeated sub-MIC/MIC exposure
271 to QACs induced mutations in regulators (*acrR*, *marR*, *soxR*, and *crp*), outer membrane
272 proteins and transporters (*mipA* and *sbmA*), and RNA polymerase (*rpoB* and *rpoC*) genes in
273 *Escherichia coli*⁵⁹. Owing the nature of biocide interactions with the bacterial cells (FIG. 2),
274 resistance mechanisms are often non-specific, with efflux and alterations in membrane
275 properties being prominent examples (Table 3).

276

277 [H2] Efflux

278 Efflux pumps facilitate the removal of toxic compounds from bacterial cells. Bacterial efflux is
279 a major global resistance mechanism that can be induced by some biocides. Efflux pumps
280 can be categorised into seven major families and superfamilies⁶⁰⁻⁶²: the drug/metabolite
281 transporter (DMT) superfamily, the major facilitator superfamily (MFS), the ATP-binding
282 cassette (ABC) superfamily, the resistance-nodulation-division (RND) superfamily, the
283 multidrug and toxic compound extrusion (MATE) superfamily, the proteobacterial antimicrobial
284 compound efflux (PACE) family, and the *p*-aminobenzyoyl-glutamate transporter family. Efflux
285 has been widely linked to increases in biocide MIC⁶³⁻⁶⁵, and decreased susceptibility to some
286 antibiotics⁶⁶⁻⁷⁰. The *qac* transporter, which belongs to the small multidrug resistance (SMR)
287 family within the DMT superfamily, exports lipophilic cations such as quaternary ammonium
288 compounds and is particularly notable in the context of biocides⁷¹. Some efflux pumps have
289 broad substrate specificity and can export both biocides and antibiotics^{60,61}. For example,

290 *oqxAB* expression in *E. coli* promotes increased resistance to benzalkonium chloride,
291 triclosan, SDS and a variety of common antibiotics⁷². However, efflux is unlikely to confer
292 resistance to in-use product concentration. The decreases in biocide susceptibility conferred
293 by efflux remain modest, with 2 to 10-fold increases in MIC typically reported^{63,70,73}; biocides
294 are typically applied at concentrations exceeding 100 to 1000-fold greater than the MIC. One
295 notable exception is the reported expression of TriABC pump conferring *P. aeruginosa*
296 resistance to triclosan (> 1mg/mL)⁷⁴.

297 Efflux pumps also play an important role in biofilm formation⁷⁵⁻⁷⁷. The expression of efflux
298 pumps in biofilms has been reported as one of the mechanisms responsible for biofilm
299 resistance to antimicrobials, particularly antibiotics⁷⁸, and studies have shown that efflux pump
300 expression is upregulated in biofilms⁷⁶.

301

302 [H2] Porins

303 As is the case of efflux pumps, changes in porin expression may confer increased resistance
304 to biocides. Porins facilitate the transport of hydrophilic solutes, including nutrients and
305 xenobiotics, across the cytoplasmic membrane (influx). General diffusion porins, such as
306 OmpC, allow a wide range of substrates to traverse the membrane, whilst others may exhibit
307 a higher degree of substrate specificity. Porins can be an intrinsic resistance mechanism, for
308 example in decreasing QAC susceptibility in *P. aeruginosa*⁷⁹, but generally the literature
309 reports modified porin expression conferring decreased susceptibility to biocides. For
310 example, decreased expression of Msp-type porins in mycobacteria results in increased
311 resistance to glutaraldehyde and ortho-phthalaldehyde and a number of antibiotics including
312 rifampicin, vancomycin, clarithromycin and erythromycin⁸⁰. Msp-type porins constitute over
313 70% of all porins in some *Mycobacterium* species and provide a route of entry for antibiotics⁸¹.
314 In *E. coli*, mutations in the porin regulators OmpR and EnvV following sublethal exposure to
315 chlorophene and povidone-iodine has been associated with changes antibiotic susceptibility
316 in vitro⁸².

317

318 [H2] Other mechanisms contributing towards resistance

319 Other acquired resistance mechanisms have been reported (Table 3). For example, in the
320 case of ionic silver, decreased susceptibility can result from multiple mechanisms (such as
321 those encoded by *silA-S* genes) that encompass efflux, reduced penetration, and
322 neutralisation and reduction of ionic silver to its inactive metallic form⁸³. A change in surface
323 charge has been implicated in reduced benzalkonium chloride efficacy in *P. aeruginosa*⁶⁷.

324 The ability of bacteria to repair damage following exposure to a biocide has generally received
325 little attention⁸⁴⁻⁸⁶, yet repair is essential to bacterial survival (FIG. 3). The impact of repair on
326 bacterial survival is better considered in the food industry, where bacterial ability to repair

327 injuries inflicted with chemical and physical agents is important to evaluate potential food
328 contamination post-processing⁸⁷.

329 Another mechanism of resistance rarely considered is pleomorphism, the ability of a bacterium
330 to change shape. For example, *Vibrio cholerae* cells can form shorter, round, rugose
331 (wrinkled) variants which are associated with enhanced biofilm formation and decreased
332 susceptibility to chlorine⁸⁸.

333 Emerging small colony variants (SCV) following antibiotic^{89,90} or biocide exposure⁹¹ is driven
334 by mutations^{92,93}. SCV are associated with several survival advantages, including intracellular
335 persistence and reduced antimicrobial susceptibility, and are implicated in disease⁹⁴. Reduced
336 antimicrobial susceptibility of SCV phenotype relies on reduced growth rate⁹⁵, reduced
337 transmembrane potential driven by alteration of the electron transport chain⁹⁶ and persistence
338 within host cell, decreasing antimicrobial exposure. The SCV phenotype is also associated
339 with biofilm formation⁹⁷.

340

341 [H2] *Coordinated expression of multiple resistance mechanisms*

342 Single mechanisms conferring bacteria resistance have been described so far. However, it is
343 now clear that bacteria can use a combination of mechanisms to survive biocide exposure as
344 part of a global response, for example a combination of efflux and changes in membrane
345 properties^{66,74,98,99}. The alteration of metabolic pathways is part of this global response^{66,98,100-}
346 ¹⁰³. Sub-lethal exposure to biocides may indirectly induce oxidative stress response regulators
347 such as *marA* and *soxS*¹⁰⁴⁻¹⁰⁶. This can impact the expression of small regulatory RNA¹⁰⁷,
348 which may also confer resistance to a range of chemotherapeutic antibiotics^{108,109}. Mutations
349 in global regulators can also impact bacterial susceptibility to biocides and promote cross
350 resistance to antibiotics. It has been reported that mutations in the two-component regulator
351 *phoPQ* and a putative Tet repressor gene (*smvR*) lead to chlorhexidine adaptation in
352 *Klebsiella pneumoniae* via an efflux mediated mechanism¹¹⁰. Whether caused by stress or
353 mutation, a change in the expression of these global regulators can induce a cascade of
354 events resulting in phenotypic changes (FIG. 3). Several publications referred to these global
355 networks as ‘triclosan resistance network’ when investigating response from *Salmonella*
356 *enterica* serovar Typhimurium to triclosan¹⁰⁰, or ‘complex cellular defence network’ describing
357 the genetic response of *S. enterica* serovar Typhimurium to chlorhexidine¹⁰¹. Metabolic
358 changes following biocide exposure has sometimes been associated with a change in
359 antibiotic susceptibility, for example aminoglycoside resistance in *Listeria monocytogenes*¹¹¹,
360 or isoniazid resistance in *Mycobacterium smegmatis*¹¹², both following triclosan exposure.

361

362 [H2] *Measuring acquired biocide resistance*

363 Whilst antibiotic resistance may be clearly defined by clinical breakpoints¹¹⁹⁻¹²¹, similar
364 definitions for 'biocide resistance' are lacking and there is little consensus as to what it should
365 be and how it should be measured⁵. In addition, whilst antibiotic resistance is linked to clinical
366 practice, there is no such concept with biocide resistance. One proposed definition is based
367 on the failure of a product at its in-use concentration to kill bacteria⁵.

368 Whilst there are no clinical breakpoints for biocides, evaluation of biocide resistance
369 inadequately aligns with tests designed for determining antibiotic efficacy, which principally
370 measure the minimum inhibitory concentration (MIC); this test measures bacterial growth in
371 medium with various concentrations of a biocide and over a period of 24 hours^{5,19}. The efficacy
372 of biocides may be substantially affected by growth medium composition and even the type of
373 plastic used in the assay plate¹²². Similarly, minimum bactericidal concentration (MBC), the
374 minimum concentration required to inactivate bacteria, is typically ascertained following 24
375 hours of contact. MBC are often determined following the use of a MIC determination protocol
376 and rarely use a neutralisation step that inactivate the biocide. Quenching the activity of a
377 biocide is paramount for evaluating the efficacy of a biocide and failing to do so can result in
378 overestimation of biocide efficacy^{25,123}.

379 Many studies define 'biocide resistance' as a change in MIC, as low as a 2-fold increase
380 (Supplementary Box 2). As the concentration of biocide within disinfectant products are
381 typically 100- to 1000-fold higher than the MIC, and the goal is typically to kill microorganisms
382 within a short contact time rather than prevent their growth, MIC-based protocols have been
383 criticised poor markers of biocide resistance: such small increases in MIC are unlikely to lead
384 to disinfection failure^{5,43}. The use of MIC distribution to determine a biocide cut off value, in
385 analogy to the definition of epidemiological cut off (ECOFF) values of antibiotic
386 susceptibility¹²⁴, has been explored⁵⁸. However, the benefit of trying to establish an association
387 between reduced susceptibility to biocide and antibiotic resistance is not certain, even if a
388 large MIC data set is used¹²⁵. Therefore, relying on MIC measurement to define 'biocide
389 resistance' is inappropriate in any context of biocide application⁵. It should not be used for
390 regulatory or intellectual property recommendations.

391 Overall, it is difficult to predict the impact of biocide exposure on emerging resistance and
392 cross-resistance to unrelated antimicrobials^{5,111} (Supplementary Box 3). The use of different
393 protocols to induce bacterial resistance following biocide exposure yields divergent results, as
394 protocols that mimic realistic exposure conditions fail to isolate resistant bacteria^{19,126}.
395 Stepwise training protocols that involve initial exposure of bacterial suspensions to increasing
396 sub-MIC concentrations, contribute to a better understanding of antimicrobial resistance
397 mechanisms^{67,104,127}, but do not accurately reflect product usage^{5,19}. Although the MIC of a
398 biocide may increase to levels close to those used in practice⁶⁷, this reduced susceptibility
399 may be readily counteracted by excipients present in formulated products¹²⁸.

400 The in-use concentration of a biocide can be reduced during product application, through
401 dilution, interaction with organic soils like dirt, surface abrasion or, in the case of antimicrobial
402 handwash, when entering drains. A lowered concentration attained following product
403 application, referred to as the 'during use' concentration, has been proposed as an appropriate
404 concentration for challenging bacteria in AMR predictive assays¹²⁹. For example, it has been
405 reported that the concentration of chlorhexidine left on surfaces were within the MIC–MBC
406 range (0.002–0.01 mg/mL) for *Escherichia coli* up to 168 hours post-application of 2%
407 chlorhexidine⁹⁸. Exposure to these concentrations resulted in stable changes in antibiotic
408 susceptibility profile, clinical resistance to ampicillin, amoxicillin and clavulanic acid,
409 ciprofloxacin, cefpodoxime, cephalotin, and a 32- to 62-fold increase in MIC and MBC to
410 chlorhexidine. There have been other approaches to determine changes in biocide resistance
411 by examining contact times necessary to achieve a reduction threshold. Such approaches
412 may provide insights that are more readily applicable to real-world scenarios¹³⁰.

413

414 **[H1] Implications of biocide exposure**

415 The impact of bacterial resistance to biocides remains a fundamental question within infection
416 control that has no easy answers, since most of the evidence comes from in vitro studies that
417 are mostly based on observing MIC increases. However, it is important to note that these
418 concentrations typically fall below the in-use concentration of the biocide. Yet, bacterial
419 survival in biocidal products and their clinical implications have been reported.

420

421 ***[H2] Examples of biocidal product contamination leading to outbreaks and pseudo-*** 422 ***outbreaks***

423 Over the years, there have been many reports of outbreak or pseudo-outbreak the later
424 corresponding to an increase in identified organisms but without evidence of infection resulting
425 from bacterial contamination of disinfectants^{131,132}. Bacterial survival in biocidal products may
426 be the result of contamination with an intrinsically resistant bacteria, as in the case of *Bacillus*
427 *cereus* spores contaminating ethyl alcohol solution¹¹, with bacteria that acquired resistance,
428 as in the case of *Serratia marcescens* contaminating a 2% aqueous chlorhexidine solution¹³³,
429 or because an ineffective biocide concentration was used following inappropriate usage of a
430 biocidal product¹³⁴⁻¹³⁷.

431 Biocidal product usage can also lead to the selection of resistant bacteria. One of the earliest
432 examples where the use of an antiseptic led to the selection for resistant bacteria was the
433 introduction of wound dressings containing 0.5% silver nitrate to combat *P. aeruginosa*
434 infection¹³⁸. Although silver nitrate was successful in eliminating most *Pseudomonas*
435 infections, *Pseudomonas* strains with a silver nitrate MIC > 0.5% were isolated in a few
436 instances, resulting in treatment failure¹³⁸. Further analysis of the patients' wound highlighted

437 a change in microbiota diversity. Whilst *Pseudomonas* was mostly controlled, the use of silver
438 nitrate enhanced the abundance of other species, particularly bacteria normally associated
439 with the gastrointestinal tract (coliforms)¹³⁸.

440 Another study reported an outbreak of *Mycobacterium massiliense* in 38 hospitals in the state
441 of Rio de Janeiro, Brazil, that occurred between August 2006 and July 2007 following video-
442 assisted surgery¹³⁹. The strains responsible for the outbreak were clinically resistant to
443 ciprofloxacin, cefoxitin and doxycycline, but also resistant to glutaraldehyde (2% w/v) which
444 was used for endoscope disinfection at the time, although the origin of the outbreak was not
445 confirmed.

446

447 **[H2] Impact of biocide exposure on emerging resistance and cross-resistance to** 448 **unrelated antimicrobials**

449 The emergence of biocide and antibiotic cross-resistance varies depending on biocide type.
450 It has been observed that, amongst 10 biocides tested, antimicrobial resistance selection in
451 *E. coli* was greatest in those exposed to chlorophene and benzalkonium chloride⁸². A smaller
452 but still notable number of resistant mutants were isolated from those exposed to
453 glutaraldehyde, chlorhexidine hydrogen peroxide and povidone-iodine. In contrast, no
454 resistant mutants were isolated from groups treated with alcohols (isopropanol, ethanol),
455 sodium hypochlorite or peracetic acid⁸². The ability of a non-intrinsically resistant bacteria to
456 survive biocide exposure at in-use concentration is not confined to less reactive biocides but
457 has also been reported with chlorine dioxide¹⁴ and glutaraldehyde¹³. Remarkably, bacterial
458 isolates were observed to be cross-resistant to unrelated biocides. For example, vegetative
459 *Bacillus subtilis* isolated from endoscope washer disinfectors were resistant to chlorine dioxide
460 (0.03%) but also to peracetic acid (2.25%) and hydrogen peroxide (7.5%), whilst comparable
461 counterpart strains were killed (>99.99% reduction in viability within 30 seconds) in 0.03%
462 chlorine dioxide¹⁴. A *Mycobacterium chelonae* isolate from endoscope washer disinfectors was
463 resistant to 2% glutaraldehyde, sodium dichloroisocyanurate (NaDCC) and Virkon®¹³. These
464 findings suggest that mechanisms allowing bacterial survival may also confer resistance to
465 chemically unrelated biocides. Unfortunately, neither study assessed changes in clinical
466 antibiotic susceptibility profiles. Oxidising agents appear to be less capable of inducing
467 resistance, which may imply a wider variety of potential targets, enhanced self-promoted
468 uptake, or a smaller number of potential adaptations to counteract biocide effects without
469 significantly compromising reproductive fitness.

470 Oxidising agents that degrade nucleic acids may also reduce the opportunity for horizontal
471 gene transfer via DNA uptake in the environment. However, exposure to subinhibitory
472 concentrations of sodium hypochlorite has been associated with decreased susceptibility to a

473 range of antibiotics in Gram-negative species, including *Salmonella* spp. and *P.*
474 *aeruginosa*^{117,140}.

475 Emerging antimicrobial resistance following biocide exposure in vitro is not limited to clinical
476 strains. The release of biocides into the environment has been shown to result in the selection
477 of resistant phenotypes. The discharge of detergent-containing wastewater into riverine
478 ecosystems has been linked to the dissemination of class-1 integrons, which increased
479 tolerance to QACs and multiple antibiotics in environmental *E. coli* isolates¹⁴¹. Repeated
480 exposure of *Salmonella enterica* serovar Typhimurium to farm disinfectants was associated
481 with acquired low-level multiple drug resistance (MDR) and decreased susceptibility to
482 antibiotics, including ciprofloxacin, in vitro¹⁴². However, these MDR strains, which exhibited
483 up-regulation of AcrAB efflux pump, were not able to disseminate in chickens compared to the
484 isogenic parent strain, nor did they show a competitive advantage when chickens were treated
485 with ciprofloxacin¹⁴².

486 There is limited evidence of the impact of biocidal products on emerging antimicrobial
487 resistance in situ. In a randomised trial, clinical and environmental samples were collected
488 from two distinct groups: individuals who used domestic biocidal products and individuals who
489 did not use them (with the exception of specific items like mouthwash and toilet bowl cleaner);
490 the authors found no evidence of differences in biocide and antibiotic cross-resistance
491 between groups¹⁴³. However, increased prevalence of potential pathogens was observed in
492 the non-user group. Another study, a longitudinal double-blind, randomized clinical trial,
493 explored the impact of biocide products (QAC- and triclosan-based) usage on change in
494 antimicrobial susceptibility profile¹⁴⁴. After 1 year of product usage, the authors reported
495 differences between the group that used antibacterial products and the group that did not. An
496 association was observed between high QAC MIC and antibiotic resistance in the product
497 'user' group. Bacterial isolates with a high QAC MIC were likely to show a high triclosan MIC
498 and resistance to one or more antibiotics.

499 All the in vitro studies mentioned so far are based on the principle of pre-exposure, whereby
500 bacteria are exposed or pre-exposed to a biocide concentration and changes in susceptibility
501 are then investigated. Co-exposure refers to exposing bacteria to two antimicrobials (for
502 example an antibiotic and a biocide) at the same time. Although this scenario might not often
503 occur in practice, it nevertheless can provide interesting observations. A study investigating
504 co-exposure of benzalkonium chloride (1-4 mg/L) and gentamicin in *Acinetobacter baumannii*
505 reported a decreased gentamicin bactericidal activity and an increased bacterial mutation
506 frequency with decreased aminoglycoside susceptibility linked to a decreased intracellular
507 antibiotic accumulation¹⁴⁵.

508

509 **[H2] Biocide exposure and antimicrobial gene maintenance and dissemination**

510 There are many examples of studies that report clinical isolates carrying multiple resistance
511 genes with an increased biocide MIC. An increasing number of studies are reporting multiple
512 resistance gene carriage in clinical and environmental isolates from settings where biocides
513 are regularly used. A previous study analysed gene carriage of efflux determinants in 53
514 *Staphylococcus aureus* clinical isolates¹⁴⁶ and reported that 83% of isolates carried plasmids
515 encoding *qacA/B* and 77% carried *smr*. Many isolates carried multiple efflux genes: 53%
516 carried *qacA/B* and *smr*, 11% carried *qacA/B*, *smr* and also *qacH*. These isolates were
517 clinically resistant to the antibiotic mupirocin and showed an elevated MIC to chlorhexidine (>
518 4 µg/mL). Multiple gene carriage, particularly of genes encoding efflux pumps, have been
519 reported in ESKAPE pathogens, including *S. aureus*¹⁴⁶⁻¹⁴⁸, *K. pneumoniae*¹⁴⁹, *A.*
520 *baumanni*^{150,151}, *P. aeruginosa*^{69,151-154}, and *Enterobacter spp.*¹⁵⁴. In these studies, the
521 implication of biocide usage in increasing gene carriage, and specific efflux genes, was not
522 ascertained although clinical isolates showed an increased MIC to various biocides.
523 Although multiple antimicrobial resistance gene carriage in environmental and clinical isolates
524 is well documented, the impact of biocide use on antimicrobial resistance gene dissemination
525 has not particularly been well investigated. A correlation between increased MIC to copper
526 and the incidence of antibiotic resistant phenotypes in *Salmonella* isolated from the feed and
527 faeces of pigs has been observed¹⁵⁵. Resistance to the antibiotics seemingly occurred
528 independently of the carriage of the copper efflux gene *pcoA*, indicating that other co-selective
529 mechanisms may have contributed towards their observations. However, in cases where
530 isolates originate from an environment where both antibiotics and biocides are used, it
531 becomes difficult to conclude the impact of biocides alone on gene dissemination. In studies
532 that have investigated bacterial clone clusters and lineages displaying an elevated biocide
533 MIC^{156,157}, or the presence of *qac* genes on class-1 integrons¹⁵⁸ along with reduced antibiotic
534 susceptibility, the role of the biocide in gene dissemination was not explored.

535
536 Co-location of resistance determinants within the same mobile genetic element will facilitate
537 co-selection and acquisition of new properties following biocide exposure^{159,160}.

538 In biofilms, the microenvironment promotes plasmid stability and may facilitate the
539 transmission of mobile genetic elements encoding resistance genes, such as QAC efflux
540 pumps (for example, *qacAB*)^{75,161}. The selective pressures exerted by biocide exposure may
541 accelerate the acquisition of antibiotic resistance genes (for example the sulfonamide
542 resistance gene *sul1*, and the β-lactamase gene *bla_{TEM}*) biofilms¹⁶².

543

544 [H1] Conclusion

545 The use of biocidal products for preservation, antisepsis and disinfection is the corner stone
546 of infection prevention and control in healthcare¹⁶³, the food industry¹⁶⁴ and home hygiene

547 settings¹⁶⁵. The use of biocidal products to reduce infection risk is an integral element of
548 combatting the spread of AMR^{166,167}. The bactericidal effectiveness of a biocide depends on
549 many factors (Table 2) and failure to understand these will contribute to bacterial survival,
550 outbreaks and potential antimicrobial resistance. The role of biocide usage on AMR continues
551 to be less well studied compared to that of chemotherapeutic antibiotics which remains the
552 driver for emerging AMR. In addition, the study of biocide effects on AMR still suffers from
553 several drawbacks, including a lack of cohesion on the definition of resistance, an
554 inappropriate use of MIC determination to measure biocide resistance, a lack of proper
555 protocols that reflect product usage to study resistance emergence and a lack of practical or
556 clinical significance on in vitro studies. Yet, our understanding of biocide impact on AMR has
557 progressed in the last 20 years. Considering a comprehensive AMR review published in
558 1999¹⁷, the principles for and mechanisms of intrinsic and acquired resistance remain broadly
559 the same. However, the use of new research tools has allowed us to understand that biocide
560 effects can be transient and biocide-led cross-resistance to different chemistries, including
561 chemotherapeutic antibiotics, might not be associated with a decreased susceptibility to the
562 biocide. We have gained a better understanding of the remarkable ability of bacteria to
563 respond to biocide exposure, notably by coordinating the expression of multiple resistance
564 mechanisms. Yet the potential risks posed by rising biocide usage remains to be addressed,
565 particularly in biofilms. There is still plenty of scope for research investigating the role of
566 biocides in increasing antibiotic resistance genes carriage and dissemination, fitness cost
567 associated with expressing multiple resistance genes and mutation rate driven by biocide
568 exposure and its impact on AMR.

569 One of the main limitations of biocide resistance is that generalisation of bacterial AMR
570 response to a given biocide exposure might be difficult to ascertain. The use of predictive
571 protocols¹²⁹ can provide practical and clinical relevance reflecting a biocide in-use condition,
572 despite being mainly based on MIC determination.

573 With the rising utilization of biocides across various environments, such as clinical, domestic,
574 veterinary, and food settings, it is fundamental that future studies address the many
575 knowledge gaps regarding the contribution of biocides to AMR. This will ensure that biocides
576 remain effective in controlling bacterial pathogens and contaminants without adding to the
577 AMR problem.

578

579

580

581 **References**

582

583 1. Fraise, A. In Principles and Practice of Disinfection, Preservation and Sterilization, 5th
584 edition. (eds. Fraise, A.P., Maillard, J.-Y. & Sattar, S.) 1-4 (Wiley-Blackwell, 2013).

585 2. Pasteur, L. On the extension of the germ theory to the etiology of certain common
586 diseases. (translated from French by Ernst HC) *Comptes Rendus de l'Académie des*
587 *Sciences*. **XC**:1033–44 (1880).

588 3. Walker, L., Levine, H. & Jucker, M. Koch's postulates and infectious proteins. *Acta*
589 *Neuropath*. **112**, 1-4 (2006).

590 4. Carter, K.C. Ignaz Semmelweis, Carl Mayrhofer, and the rise of germ theory. *Med. Hist.*
591 **29**, 33–53 (1985).

592 5. Maillard, J.-Y. et al. Does microbicide use in consumer products promote antimicrobial
593 resistance? A critical review and recommendations for a cohesive approach to risk
594 assessment. *Microb. Drug Res.* **19**, 344-354 (2013).

595 This opinion paper highlights the issues associated with a lack of definition of “biocide
596 resistance” and with a lack of consensus for measuring bacterial resistance to biocides.

597

598

599 6. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR).
600 Assessment of the Antibiotic Resistance Effects of Biocides. European Commission
601 http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_021.pdf
602 (2009)

603 7. Mueller, S., Shlag, S. & Beraud, L. The biocides market in the times of coronavirus.,
604 S&P Global Commodity Insights, Articles & Reports; Sept 10,2020.
605 [https://www.spglobal.com/commodityinsights/en/ci/research-analysis/the-biocides-](https://www.spglobal.com/commodityinsights/en/ci/research-analysis/the-biocides-market-in-the-times-of-coronavirus.html)
606 [market-in-the-times-of-coronavirus.html](https://www.spglobal.com/commodityinsights/en/ci/research-analysis/the-biocides-market-in-the-times-of-coronavirus.html) (2023)

607 8. Maillard, J.-Y. Resistance of bacteria to biocides. *Microbiol. Spectrum*. **6**, ARBA-0006-
608 2017 (2018).

609 9. Ko, S., An, H.S., Bang, J.H. & Park, SW. An outbreak of *Burkholderia cepacia* complex
610 pseudobacteremia associated with intrinsically contaminated commercial 0.5%
611 chlorhexidine solution. *Am. J. Infec. Control*. **43**, 266-268 (2015).

612 10. Nakashima, A.K., McCarthy, M.A., Martone, W.J., Anderson, R.L. Epidemic septic
613 arthritis caused by *Serratia marcescens* and associated with benzalkonium chloride
614 antiseptic. *J. Clin. Microbiol.* **25**, 1014–1018 (1987).

615 11. Hsueh, P.-R. et al. Nosocomial pseudoepidemic caused by *Bacillus cereus* traced to
616 contaminated ethyl alcohol from a liquor factory. *J. Clin. Microbiol.* **37**, 2280-2284
617 (1999).

- 618 12. Poole, K. Mechanisms of bacterial biocide and antibiotic resistance. *J. Appl. Microbiol.*
619 **92**, 55S-64S (2002).
- 620 13. Griffiths, P.A., Babb, J.R., Bradley, C.R. & Fraise, A.P. Glutaraldehyde resistant
621 *Mycobacterium chelonae* from endoscope washer disinfectors. *J. Appl. Microbiol.* **82**,
622 519-526 (1997).
- 623 14. Martin, D.J.H., Denyer, S.P., McDonnell, G. & Maillard, J.-Y. Resistance and cross-
624 resistance to oxidising agents of bacterial isolates from endoscope washer disinfectors.
625 *J. Hosp. Infect.* **69**, 377-383 (2008).
- 626 This paper presents evidence of vegetative bacteria isolated from an endoscope washer
627 disinfectant (using chlorine dioxide high-level disinfection), resistant to in use concentration of
628 chlorine dioxide and other reactive biocides.
- 629
- 630 15. Martin, D.J.H, Wessgate, R., Denyer, S.P., McDonnell, G. & Maillard, J.-Y. *Bacillus*
631 *subtilis* vegetative isolate surviving chlorine dioxide exposure: an elusive mechanism of
632 resistance. *J. Appl. Microbiol.* **119**, 1541-1551 (2015).
- 633 16. Russell, A.D. Biocides – Mechanisms of action and microbial resistance. *World J.*
634 *Microbiol. Biotechnol.* **8**, 58-59 (1992).
- 635 17. McDonnell, G. & Russell, A.D. Antiseptics and disinfectants: activity, action, and
636 resistance. *Clin. Microbiol. Rev.* **12**, 147-79 (1999).
- 637 This is a reference review highlighting the limitation of biocide efficacy depending on their
638 chemistry, propensity for microbial resistance resulting to exposure to a low concentration of
639 a biocide.
- 640 18. Russell, A.D. Biocide use and antibiotic resistance: the relevance of laboratory findings
641 to clinical and environmental situations. *Lancet Infect. Dis.* **3**, 794-803 (2003).
- 642 19. Maillard, J.-Y. Impact of benzalkonium chloride, benzethonium chloride and
643 chloroxylenol on bacterial resistance and cross-resistance to antimicrobials. *J. Appl.*
644 *Microbiol.* **133**, 3322-3346 (2022).
- 645 20. Wand, M.E. & Sutton, J.M. Efflux-mediated tolerance to cationic biocides, a cause for
646 concern? *Microbiology.* **168**, 1263 (2022).
- 647 21. Vijayakumar, R. & Sandle, T. A review on biocide reduced susceptibility due to plasmid-
648 borne antiseptic-resistant genes – special notes on pharmaceutical environmental
649 isolates. *J. Appl. Microbiol.* **126**, 1011-1022 (2019).
- 650 22. Jones, I.A. & Joshi, L. Biocide use in the antimicrobial era: a review. *Molecules* **26**, 2276
651 (2021).
- 652 23. Al-Adham, I., Haddadin, R. & Collier, P. Types of microbicidal and microbistatic agents.
653 In Principles and Practice of Disinfection, Preservation and Sterilization, 5th edn (eds.
654 Fraise, A.P., Maillard, J.-Y. & Sattar, S.), 5-70 (Wiley-Blackwell, 2013)

- 655 24. Singer, A.C., Shaw, H., Rhodes, V. & Hart, A. Review of antimicrobial resistance in the
656 environment and its relevance to environmental regulators. *Front. Microbiol.* **7**, 1728
657 (2016).
- 658 25. Leggett, M.J., Setlow, P., Sattar, S.A. & Maillard, J.-Y. Assessing the activity of
659 microbicides against bacterial spores: knowledge and pitfalls. *J. Appl. Microbiol.* **120**,
660 1174-1180 (2016).
- 661 26. Forbes, S. et al. Formulation of biocides increases antimicrobial potency and mitigates
662 the enrichment of nonsusceptible bacteria in multispecies. *Appl. Environ. Microbiol.* **83**,
663 e3054-16 (2017).
- 664 27. Maillard, J.-Y. Bacterial target sites for biocide action. *J. Appl. Microbiol.* **92**, 16S-27S
665 (2002).
- 666 28. Sani, M-A. et al. Maculatin 1.1 disrupts *Staphylococcus aureus* lipid membranes via a pore
667 mechanism. *Antimicrob. Agents Chemother.* **57**, 3593-600 (2013).
- 668 29. Johnston, M.D., Hanlon, G.W., Denyer, S.P. & Lambert, R.J.W. Membrane damage to
669 bacteria caused by single and combined biocides. *J. Appl. Microbiol.* **94**, 1015-1023
670 (2003).
- 671 30. Barros, A.C., Melo, L.F. & Pereira, A. A multi-purpose approach to the mechanisms of
672 action of two biocides (benzalkonium chloride and dibromonitropropionamide):
673 discussion of *Pseudomonas fluorescens*' viability and death. *Front. Microbiol.* **13**,
674 842414 (2022).
- 675 31. Linley, E., Denyer, S.P., McDonnell, G., Simons, C., Maillard, J.-Y. Use of hydrogen
676 peroxide as a biocide: new consideration of its mechanisms of biocidal action. *J.*
677 *Antimicrob. Chemother.* **67**, 1589-1596 (2012).
- 678 32. Setlow, B., Atluri, S., Kitchel, R., Koziol-Dube, K. & Setlow, P. Role of dipicolinic acid in
679 resistance and stability of spores of *Bacillus subtilis* with or without DNA-protective α/β -
680 type small acid-soluble proteins. *J. Bacteriol.* **188**, 3740-3747 (2006).
- 681 33. Leggett, M.J. et al. Resistance to and killing by the sporicidal microbicide peracetic acid.
682 *J. Antimicrob. Chemother.* **70**, 773-779 (2015).
- 683 34. Alkhalifa, S. et al. Analysis of the destabilization of bacterial membranes by quaternary
684 ammonium compounds: A combined experimental and computational study.
685 *ChemBioChem* **21**, 1510-1516 (2020).
- 686 35. Bore, E. et al. Adapted tolerance to benzalkonium chloride in *Escherichia coli* K-12
687 studied by transcriptome and proteome analyses. *Microbiology (Reading)* **153**, 935-946
688 (2007).
- 689 36. Roth, M. et al. Transcriptomic analysis of *E. coli* after exposure to a sublethal
690 concentration of hydrogen peroxide revealed a coordinated up-regulation of the cysteine
691 biosynthesis pathway. *Antioxidants (Basel)* **11**, 655 (2022).

- 692 37. Denyer, S.P. & Maillard, J.-Y. Cellular impermeability and uptake of biocides and
693 antibiotics in Gram-negative bacteria. *J. Appl. Microbiol.* **92**, 35S-45S (2002).
- 694 38. Denyer, S.P. Mechanisms of action of biocides. *Int. Biodeter.* **26**, 89-100 (1990).
- 695 39. McMurry, L.M., Oethinger, M. & Levy, S.B. Triclosan targets lipid synthesis. *Nature* **394**,
696 531-532 (1998).
- 697 40. Simões, L.C. et al. Persister cells in a biofilm treated with a biocide. *Biofouling* **27**, 403-
698 411 (2011).
- 699 41. Fernandes, S., Gomes, I.B., Sousa, S.F. & Simões, M. Antimicrobial susceptibility of
700 persister biofilm cells of *Bacillus cereus* and *Pseudomonas fluorescens*. *Microorganisms*
701 **10**, 160 (2022).
- 702 42. Maillard, J.-Y. Usage of antimicrobial biocides and products in the healthcare
703 environment: efficacy, policies, management and perceived problems. *Ther. Clin. Risk*
704 *Manag.* **1**, 340-370 (2005).
- 705 43. Russell, A.D. & McDonnell, G. Concentration: a major factor in studying biocidal action.
706 *J. Hosp. Infect.* **44**, 1-3 (2000).
- 707 44. Lambert, P.A. Cellular impermeability and uptake of biocides and antibiotics in Gram-
708 positive bacteria and mycobacteria. *J. Appl. Microbiol.* **92**, 46S-54S (2002).
- 709 45. Lambert, R.J.W., Hanlon, G.W. & Denyer, S.P. The synergistic effect of
710 EDTA/antimicrobial combinations on *Pseudomonas aeruginosa*. *J. Appl. Microbiol.* **96**,
711 244-253 (2004).
- 712 46. Leggett, M.J., McDonnell, G., Denyer, S.P., Setlow, P. & Maillard, J.-Y. Bacterial spore
713 structures and their protective role in biocide resistance. *J. Appl. Microbiol.* **113**, 485-
714 498 (2012).
- 715 47. Maillard, J.-Y. Innate resistance to sporicides and potential failure to decontaminate. *J.*
716 *Hosp. Infect.* **77**, 204-209 (2011).
- 717 48. Vickery, K. et al. Presence of biofilm containing viable multiresistant organisms despite
718 terminal cleaning on clinical surfaces in an intensive care unit. *J. Hosp. Infect.* **80**, 52-
719 55 (2012).
- 720 49. Hu, H. et al. Intensive care unit environmental surfaces are contaminated by multidrug-
721 resistant bacteria in biofilms: combined results of conventional culture, pyrosequencing,
722 scanning electron microscopy, and confocal laser microscopy. *J. Hosp. Infect.* **91**, 35-
723 44 (2015).
- 724 50. Ledwoch, K. et al. Beware biofilm! dry biofilms containing bacterial pathogens on
725 multiple healthcare surfaces; a multi-centre study. *J. Hosp. Infect.* **100**, E47-56 (2018).
- 726 51. Ledwoch, K. et al. Is a reduction in viability enough to determine biofilm susceptibility to
727 a biocide? *Infect. Control Hosp. Epidemiol.* **42**, 1486-1492 (2021).

- 728 52. Bridier, A., Dubois-Brissonnet, F., Greub, G., Thomas, V. & Briandet, R. Dynamics of
729 the action of biocides in *Pseudomonas aeruginosa* biofilms. *Antimicrob. Agents*
730 *Chemother.* **55**, 2648-2654 (2011).
- 731 53. Stewart, P.S. Antimicrobial tolerance in biofilms. *Microbiol. Spectr.* **3**, 10.1128 (2015).
- 732 54. Bas, S., Kramer, M. & Stopar, D. Biofilm surface density determines biocide
733 effectiveness. *Front. Microbiol.* **8**, 2443 (2017).
- 734 55. Araújo, P.A., Mergulhão, F., Melo, L. & Simões, M. The ability of an antimicrobial agent
735 to penetrate a biofilm is not correlated with its killing or removal efficiency. *Biofouling* **30**,
736 673-683 (2014).
- 737 56. Wood, T.K., Knabel, S.J. & Kwana, B.W. Bacterial persister cell formation and
738 dormancy. *Appl. Environ. Microbiol.* **79**, 7116-7121 (2013).
- 739 57. Podlesek, Z. & Bertok, D.Z. The DNA damage inducible SOS response is a key player
740 in the generation of bacterial persister cells and population wide tolerance. *Front.*
741 *Microbiol.* **4**, 1785 (2020).
- 742 58. Ciusa, M.L. et al. A novel resistance mechanism to triclosan that suggests horizontal
743 gene transfer and demonstrates a potential selective pressure for reduced biocide
744 susceptibility in clinical strains of *Staphylococcus aureus*. *Int. J. Antimicrob. Agents* **40**,
745 210-220 (2012).
- 746 59. Jia, Y., Lu, H. & Zhua, L. Molecular mechanism of antibiotic resistance induced by mono-
747 and twin-chained quaternary ammonium compounds. *Sci. Total Environ.* **832**, 155090
748 (2022).
- 749 60. Schindler, B.D. & Kaatz, G.W. Multidrug efflux pumps of Gram-positive bacteria. *Drug*
750 *Res. Updates* **27**, 1-13 (2016).
- 751 61. Poole, K. Outer membranes and efflux: the path to multidrug resistance in Gram-
752 negative bacteria. *Curr. Pharm. Biotechnol.* **3**, 77-98 (2002).
- 753 62. Chitsaz, M., Brown, M.H. The role played by drug efflux pumps in bacterial multidrug
754 resistance. *Essays Biochem.* **61**, 127-139. (2017).
- 755 63. Rajamohan, G., Srinivasan, V.B. & Gebreyes, W.A. Novel role of *Acinetobacter*
756 *baumannii* RND efflux transporters in mediating decreased susceptibility to biocides. *J.*
757 *Antimicrob. Chemother.* **65**, 228-232 (2010).
- 758 64. LaBreck, P.T. et al. Systematic analysis of efflux pump-mediated antiseptic resistance
759 in *Staphylococcus aureus* suggests a need for greater antiseptic stewardship. *mSphere*
760 **5**, e00959-19 (2020).
- 761 65. Wand, M.E., Darby, E.M., Blair, J.M.A. & Sutton, J.M. Contribution of the efflux pump
762 AcrAB-TolC to the tolerance of chlorhexidine and other biocides in *Klebsiella* spp. *J.*
763 *Med. Microbiol.* **71**, 001496 (2022).

- 764 66. Fernández-Cuenca, F. et al. Reduced susceptibility to biocides in *Acinetobacter*
765 *baumannii*: association with resistance to antimicrobials, epidemiological behaviour,
766 biological cost and effect on the expression of genes encoding porins and efflux pumps.
767 *J. Antimicrob. Chemother.* **70**, 3222-3229 (2015).
- 768 67. Kim, M. et al. Widely used benzalkonium chloride disinfectants can promote antibiotic
769 resistance. *Appl. Environ. Microbiol.* **84**, 1201-1218 (2018).
- 770 68. Nordholt, N., Kanaris, O., Schmidt, S.B.I. & Schreiber, F. Persistence against
771 benzalkonium chloride promotes rapid evolution of tolerance during periodic
772 disinfection. *Nature Comm.* **12**, 6792 (2021).
- 773 69. Amsalu, A. et al. Efflux pump-driven antibiotic and biocide cross-resistance in
774 *Pseudomonas aeruginosa* isolated from different ecological niches: A case study in the
775 development of multidrug resistance in environmental hotspots. *Microorganisms* **8**, 1647
776 (2020).
- 777 70. Sánchez, M.B. et al. Predictive studies suggest that the risk for the selection of antibiotic
778 resistance by biocides is likely low in *Stenotrophomonas maltophilia*. *PLoS ONE* **10**,
779 e0132816 (2015).
- 780 71. Bay, D.C. & Turner, R.J. Diversity and evolution of the small multidrug resistance protein
781 family. *BMC Evol. Biol.* **9**, 140 (2009). doi: 10.1186/1471-2148-9-140.
- 782 72. Hansen, L.S., Jensen, L.B., Sørensen, H.I. & Sørensen, S.J. Substrate specificity of the
783 OqxAB multidrug resistance pump in *Escherichia coli* and selected enteric bacteria. *J.*
784 *Antimicrob. Chemother.* **60**, 145-147 (2007).
- 785 73. Kaatz, G.W. & Seo, S.M. Effect of substrate exposure and other growth condition
786 manipulations on *norA* expression. *J. Antimicrob. Chemother.* **54**, 364-369 (2004).
- 787 74. Mima, T., Joshi, S., Gomez-Escalada, M. & Schweizer, H.P. Identification and
788 characterization of TriABC-OpmH, a triclosan efflux pump of *Pseudomonas aeruginosa*
789 requiring two membrane fusion proteins. *J. Bacteriol.* **189**, 7600-7609 (2007).
- 790 75. Buffet-Bataillon, S., Tattevin, P., Maillard, J.-Y., Bonnaure-Mallet, M. & Jolivet-Gougeon,
791 A. Efflux pump induction by quaternary ammonium compounds and fluoroquinolone
792 resistance in bacteria. *Future Microbiol.* **11**, 81-92 (2016).
- 793 76. Reza, A., Sutton, J.M. & Rahman, K.M. Effectiveness of efflux pump inhibitors as biofilm
794 disruptors and resistance breakers in Gram-negative (ESKAPEE) bacteria. *Antibiotics.*
795 **8**, 229 (2019).
- 796 77. Kvist, M., Hancock, V. & Klemm, O.P. Inactivation of efflux pumps abolishes bacterial
797 biofilm formation. *Appl. Environ. Microbiol.* **74**, 7376-7382 (2008).
- 798 78. Soto, S.M. Role of efflux pumps in the antibiotic resistance of bacteria embedded in a
799 biofilm. *Virulence* **4**, 223-229 (2013).

- 800 79. Chevalier, S. et al. Structure function and regulation of *Pseudomonas aeruginosa*
801 porins. *FEMS Microbiol. Rev.* **41**, 698-772 (2017).
- 802 80. Svetlíková, Z et al. Role of porins in the susceptibility of *Mycobacterium smegmatis* and
803 *Mycobacterium chelonae* to aldehyde-based disinfectants and drugs. *Antimicrob.*
804 *Agents Chemother.* **53**, 4015-4018 (2009).
- 805 81. Stahl, C. et al. MspA provides the main hydrophilic pathway through the cell wall of
806 *Mycobacterium smegmatis*. *Mol. Microbiol.* **40**, 451-464 (2001).
- 807 82. Pereira, B.M.P., Wang, X.K. & Tagkopoulos, I. Biocide-induced emergence of antibiotic
808 resistance in *Escherichia coli*. *Front. Microbiol.* **12**, 640923 (2021).
- 809 83. Silver, S. Bacterial silver resistance: molecular biology and uses and misuse of silver
810 compounds. *FEMS Microbiol. Rev.* **27**, 341-353 (2003).
- 811 84. Casado Muñoz, M.C. et al. Comparative proteomic analysis of a potentially probiotic
812 *Lactobacillus pentosus* MP-10 for the identification of key proteins involved in antibiotic
813 resistance and biocide tolerance. *Int. J. Food Microbiol.* **222**, 8-15 (2016).
- 814 85. Allen, M.J., White, G.F. & Morby, A.P. The response of *Escherichia coli* to exposure to
815 the biocide polyhexamethylene biguanide. *Microbiology* **152**, 989-1000 (2006).
- 816 86. Motgatla, R.M., Gouws, P.A. & Brözel, V.S. Mechanisms contributing to hypochlorous
817 acid resistance of a *Salmonella* isolate from a poultry-processing plant. *J. Appl.*
818 *Microbiol.* **92**, 566-573 (2002).
- 819 87. Wu, C.H. A review of microbial injury and recovery methods in food. *Food Microbiol.* **25**,
820 735-744 (2008).
- 821 88. Yildiz, F.H. & Schoolnik, G.K. *Vibrio cholerae* O1 E1 Tor: identification of a gene cluster
822 required for the rugose colony type, exopolysaccharide production, chlorine resistance
823 and biofilm formation. *Proc. Natl. Acad. Sci. USA* **96**, 4028-4033 (1999).
- 824 89. Koska, M. et al. Distinct long- and short-term adaptive mechanisms in *Pseudomonas*
825 *aeruginosa*. *Microbiol. Spectr.* **10**, e0304322 (2022).
- 826 90. Keim, K.C., George, I.K., Reynolds, L. & Smith, A.C. The clinical significance of
827 *Staphylococcus aureus* small colony variants. *Lab. Med.* **54**, 227–234 (2023).
- 828 91. Seaman, P.F., Ochs, D. & Day, M.J. Small-colony variants: a novel mechanism for
829 triclosan resistance in methicillin -resistant *Staphylococcus aureus*. *J. Antimicrob.*
830 *Chemother.* **59**, 43-50 (2007).
- 831 92. Pitton, M. et al. Mutation to *ispA* produces stable small-colony variants of *Pseudomonas*
832 *aeruginosa* that have enhanced aminoglycoside resistance. *Antimicrob. Agents*
833 *Chemother.* **66**, e0062122 (2022).
- 834 93. Zhou, S., Rao, Y., Li, J., Huang, Q. & Rao, X. *Staphylococcus aureus* small-colony
835 variants: Formation, infection, and treatment. *Microbiol. Res.* **260**, 127040 (2022).

- 836 94. Fischer, A.J. Small colonies, bigger problems? New evidence that *Staphylococcus*
837 *aureus* small colony variants can worsen lung inflammation in cystic fibrosis rats. *Infect.*
838 *Immun.* **90**, e0041322 (2022).
- 839 95. McNamara, P.J. & Proctor, R.A. *Staphylococcus aureus* small colony variants, electron
840 transport and persistent infections. *Int. J. Antimicrob. Agents.* **14**, 117-122 (2000).
- 841 96. Gilman, S. & Saunders, V.A. Accumulation of gentamicin by *Staphylococcus aureus*:
842 the role of the transmembrane electrical potential. *J. Antimicrob. Chemother.* **17**, 37-44
843 (1986).
- 844 97. Guo, H. et al. Biofilm and small colony variants-an update on *Staphylococcus aureus*
845 strategies toward drug resistance. *Int. J. Mol. Sci.* **23**, 1241 (2022).
- 846 98. Wesgate, R., Fanning, S., Hu, Y. & Maillard, J.-Y. The effect of exposure to microbicide
847 residues at “during use” concentrations on antimicrobial susceptibility profile, efflux,
848 conjugative plasmid transfer and metabolism of *Escherichia coli*. *Antimicrob. Agents*
849 *Chemother.* **64**, e01131-20 (2020).
- 850 99. Bischofberger, A.M., Baumgartner, M., Pfrunder-Cardozo, K.R., Allen, R.C. & Hall, A.R.
851 Associations between sensitivity to antibiotics, disinfectants and heavy metals in natural,
852 clinical and laboratory isolates of *Escherichia coli*. *Environ. Microbiol.* **22**, 2664-2679
853 (2020).
- 854 100. Webber, M.A., Coldham, N.G., Woodward, M.J. & Piddock, L.J.V. Proteomic analysis of
855 triclosan resistance in *Salmonella enterica* serovar Typhimurium. *J. Antimicrob.*
856 *Chemother.* **62**, 92-97 (2008).
- 857 101. Condell, O. et al. Comparative analysis of *Salmonella* susceptibility and tolerance to the
858 biocide chlorhexidine identifies a complex cellular defense network. *Front Microbiol.* **5**,
859 373 (2014).
- 860 This paper clearly identifies the expression of multiple mechanisms in response to biocide
861 exposure. It rightly refers for the first time to a complex cellular defense network, which
862 highlights that bacterial response to biocide stress does not rely on one mechanisms but a
863 combination of mechanisms.
- 864
- 865 102. Curiao, T. et al. Multiple adaptive routes of *Salmonella enterica* Typhimurium to biocide
866 and antibiotic exposure. *BMC Genomics* **17**, 491 (2016).
- 867 103. Pi, B.R., Yu, D.L., Hua, X.T., Ruan, Z., Yu, Y.S. Genomic and transcriptome analysis of
868 triclosan response of a multidrug-resistant *Acinetobacter baumannii* strain, MDR-ZJ06.
869 *Arch. Microbiol.* **199**, 223-230 (2017).
- 870 104. Curiao, T. et al. Polymorphic variation in susceptibility and metabolism of triclosan-
871 resistant mutants of *Escherichia coli* and *Klebsiella pneumoniae* clinical strains obtained

- 872 after exposure to biocides and antibiotics. *Antimicrob. Agents Chemother.* **59**, 3413-
873 3423 (2015).
- 874 105. McMurry, L.M., Oethinger, M. & Levy, S.B. Overexpression of *marA*, *soxS*, or *acrAB*
875 produces resistance to triclosan in laboratory and clinical strains of *Escherichia coli*.
876 *FEMS Microbiol. Lett.* **166**, 305-309 (1998).
- 877 106. Bailey, A.M. et al. Exposure of *Escherichia coli* and serovar Typhimurium to triclosan
878 induces a species-specific response, including drug detoxification. *J. Antimicrob.*
879 *Chemother.* **64**, 973-985 (2009).
- 880 107. Dejoies, L., Le Neindre, K., Reissier, S., Felden, B. & Cattoir, V. Distinct expression
881 profiles of regulatory RNAs in the response to biocides in *Staphylococcus aureus* and
882 *Enterococcus faecium*. *Sci. Reports* **11**, 6892 (2021).
- 883 This paper documents the impact of biocide exposure at a sub-inhibitory concentration on the
884 expression of sRNA in *S. aureus* and *Enterococcus faecium*. The authors demonstrate sRNA-
885 mediated responses were mostly repressed and hypothesise that this will lead to specific
886 bacterial response and adaptation to biocides.
- 887
- 888 108. Demple, B. Redox signaling and gene control in the *Escherichia coli* *soxRS* oxidative
889 stress regulon - a review. *Gene* **179**, 53-57 (1996).
- 890 109. Koutsolioutsou, A., Pena-Llopis, S. & Demple, B. Constitutive *soxR* mutations contribute
891 to multiple-antibiotic resistance in clinical *Escherichia coli* isolates. *Antimicrob. Agents*
892 *Chemother.* **49**, 2746-2752 (2005).
- 893 110. Wand, M.E., Bock, L.J., Bonney, L.C. & Sutton, J.M. Mechanisms of increased
894 resistance to chlorhexidine and cross-resistance to colistin following exposure of
895 *Klebsiella pneumoniae* clinical isolates to chlorhexidine. *Antimicrob. Agents Chemother.*
896 **61**, e01162-16 (2016).
- 897 111. Kastbjerg, V.G., Hein-Kristensen, L. & Gram, L. Triclosan-induced aminoglycoside-
898 tolerant *Listeria monocytogenes* isolates can appear as small-colony variants.
899 *Antimicrob. Agents Chemother.* **58**, 3124-3132 (2014).
- 900 112. McMurry, L.M., McDermott, P.F. & Levy, S.B. Genetic evidence that *InhA* of
901 *Mycobacterium smegmatis* is a target for triclosan. *Antimicrob. Agents Chemother.* **43**,
902 711-713 (1999).
- 903 113. Zhang, M., Chen, L. Ye, C. & Yu, X. Co-selection of antibiotic resistance via copper sock
904 loading on bacteria from drinking water bio-filter. *Environ. Poll.* **233**, 132-141 (2018).
- 905 114. Fernando, D.M., Xu, W., Loewen, P.C., Zhanel, G.G. & Kumar, A. Triclosan can select
906 for an *AdelJK*-overexpressing mutant of *Acinetobacter baumannii* ATCC 17978 that
907 displays reduced susceptibility to multiple antibiotics. *Antimicrob. Agents Chemother.*
908 **58**, 6424-6431 (2014).

- 909 115. Mc Cay, P.H., Ocampo-Sosa, A.O & Fleming, G.T.A. Effect of subinhibitory
910 concentrations of benzalkonium chloride on the competitiveness of *Pseudomonas*
911 *aeruginosa* grown in continuous culture. *Microbiology* **156**, 30-38 (2010).
- 912 116. Mavri, A. & Smole Možina, S. Development of antimicrobial resistance in *Campylobacter*
913 *jejuni* and *Campylobacter coli* adapted to biocides. *Int. J. Food Microbiol.* **160**, 304-312
914 (2013).
- 915 118. Tong, C., Hu, H., Chen, G, Li, Z., Li, A. & Zhang, J. Chlorine disinfectants promote
916 microbial resistance in *Pseudomonas* sp. *Environ. Res.* **199**, 111296 (2021).
- 917 117. Ben Miloud, S., Ali, M.M., Boutiba, I., Van Houdt, R. & Chouchani, C. First report of cross
918 resistance to silver and antibiotics in *Klebsiella pneumoniae* isolated from patients and
919 polluted water in Tunisia. *Water. Environ. J.* **35**, 730-739 (2021).
- 920 119. International Organization for Standardization. ISO: 20776-1. Clinical laboratory testing
921 and in vitro diagnostic test systems: susceptibility testing of infectious agents and
922 evaluation of performance of antimicrobial susceptibility test devices. Part 1. Reference
923 method for testing the in vitro activity of antimicrobial agents against rapidly growing
924 aerobic bacteria involved in infectious diseases. British Standard Institute, London,
925 United Kingdom (2006).
- 926 120. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint
927 tables for interpretation of MICs and zone diameters. Version 4.0. (2014).
- 928 121. Andrews, J.M. BSAC Working Party on Susceptibility Testing. BSAC standardized disc
929 susceptibility testing method (version 8). *J. Antimicrob. Chemother.* **64**, 454-489 (2009).
- 930 122. Bock, L.J., Hind, C.K., Sutton, J.M. & Wand, M.E. Growth media and assay plate
931 material can impact on the effectiveness of cationic biocides and antibiotics against
932 different bacterial species. *Lett. Appl. Microbiol.* **66**, 368-377 (2018). doi:
933 10.1111/lam.12863.
- 934 123. Kampf, G. Suitability of methods to determine resistance to biocidal active substances
935 and disinfectants - A systematic review. *Hygiene* **2**, 109-119 (2022).
- 936 124. Kahlmeter, G. et al. European harmonization of MIC breakpoints for antimicrobial
937 susceptibility testing of bacteria. *J. Antimicrob. Chemother.* **52**, 145-148 (2003).
- 938 125. Coelho et al. The use of machine learning methodologies to analyse antibiotic and
939 biocide susceptibility in *Staphylococcus aureus*. *PLoS ONE* **8**, e55582 (2013).
- 940 126. Walsh, S.E. et al. Development of bacterial resistance to several biocides and effects
941 on antibiotic susceptibility. *J. Hosp. Infect.* **55**, 98-107 (2003).
- 942 127. Alonso-Calleja, C., Guerrero-Ramos, E., Alonso-Hernando, A. & Capita, R. Adaptation
943 and cross-adaptation of *Escherichia coli* ATCC 12806 to several food-grade biocides.
944 *Food Control.* **56**, 86-94 (2015).

- 945 128. Cowley, N.L. et al. Effects of formulation on microbicide potency and mitigation of the
946 development of bacterial insusceptibility. *Appl. Environ. Microbiol.* **81**, 7330-7338
947 (2015).
- 948 129. Wesgate, R., Grasha, P. & Maillard, J.-Y. Use of a predictive protocol to measure the
949 antimicrobial resistance risks associated with biocidal product usage. *Am. J. Infect.*
950 *Control* **44**, 458-464 (2016).
- 951 130. Randall, L.P. et al. Commonly used farm disinfectants can select for mutant *Salmonella*
952 *enterica* serovar Typhimurium with decreased susceptibility to biocides and antibiotics
953 without compromising virulence. *J. Antimicrob. Chemother.* **60**, 1273-1280 (2007).
- 954 131. Weber, D.J., Rutala, W.A. & Sickbert-Bennett, E.E. Outbreaks associated with
955 contaminated antiseptics and disinfectants. *Antimicrob. Agents Chemother.* **51**, 4217-
956 4224 (2007).
- 957 This review presents evidence of bacterial contamination of biocidal products, and highlights
958 the reasons for product failure, mainly contamination with an intrinsically resistant
959 bacterium/spore or product misuse.
- 960
- 961 132. Maillard, J.-Y. Bacterial resistance to biocides. In *Blocks' Disinfection, Sterilization and*
962 *Preservation*, 6th edition. (eds McDonnell, G. & Hansen, J.) 44-67 (Philadelphia: Wolters
963 Kluwer, 2020).
- 964 133. de Frutos, M. et al. *Serratia marcescens* outbreak due to contaminated 2% aqueous
965 chlorhexidine. *Enfermedades Infecciosas y Microbiología Clínica* **35**, 624-629 (2016).
- 966 134. Anyiwo, C.E., Coker, A.O. & Daniel, S.O. *Pseudomonas aeruginosa* in postoperative
967 wounds from chlorhexidine solutions. *J. Hosp. Infect.* **3**, 189–191(1982).
- 968 135. Wishart, M.M. & Riley, T.V. Infection with *Pseudomonas maltophilia* hospital outbreak
969 due to contaminated disinfectant. *Med. J. Aust.* **2**, 710–712 (1976).
- 970 136. Georgia Division of Public Health. Abscesses in an allergy practice due to
971 *Mycobacterium chelonae*. *Georgia Epidemiol. Rep.* **6**,2 (1960).
- 972 137. Guinness, M. & Levey, J. Contamination of aqueous dilutions of Resiguard disinfectant
973 with *Pseudomonas*. *Med. J. Aust.* **2**, 392 (1976).
- 974 138. Cason, J.S., Jackson, D.M., Lowbury, E.J. & Ricketts, C.R. Antiseptic and septic
975 prophylaxis for burns: use of silver nitrate and of isolators. *Br. Medic. J.* **2**, 1288-1294
976 (1966).
- 977 139. Duarte, R.S., Lourenco, M.C.S., Fonseca, L.D. et al. Epidemic of postsurgical infections
978 caused by *Mycobacterium massiliense*. *J. Clin. Microbiol.* **47**, 2149-2155 (2009).
- 979 140. Molina-González, D, Alonso-Calleja, C., Alonso-Hernando, A. & Capita, R. Effect of sub-
980 lethal concentrations of biocides on the susceptibility to antibiotics of multi-drug resistant
981 *Salmonella enterica* strains. *Food Control.* **40**, 329-334 (2014).

- 982 141. Amos, G.C.A. et al. The widespread dissemination of integrons throughout bacterial
983 communities in a riverine system. *ISME J.* **12**, 681-691 (2018).
- 984 142. Randall, L.P. et al. Fitness and dissemination of disinfectant-selected multiple-antibiotic-
985 resistant (MAR) strains of *Salmonella enterica* serovar Typhimurium in chickens. *J.*
986 *Antimicrob. Chemother.* **61**, 156-162 (2008).
- 987 143. Cole, E.C. et al. Investigation of antibiotic and antibacterial agent cross-resistance in
988 target bacteria from homes of antibacterial product users and nonusers. *J. Appl.*
989 *Microbiol.* **95**, 664-676 (2003).
- 990 144. Carson, R.T., Larson, E., Levy, S.B., Marshall, B.M. & Aiello, A.E. Use of antibacterial
991 consumer products containing quaternary ammonium compounds and drug resistance
992 in the community. *J. Antimicrob. Chemother.* **62**, 1160-1162 (2008).
- 993 145. Short, F.L. et al. Benzalkonium chloride antagonises aminoglycoside antibiotics and
994 promotes evolution of resistance. *EBiomedicine* **73**, 103653 (2021).
- 995 146. Liu, Q., Zhao, H., Han, L., Shu, W., Wu, Q. & Ni, Y. Frequency of biocide-resistant genes
996 and susceptibility to chlorhexidine in high-level mupirocin-resistant, methicillin-resistant
997 *Staphylococcus aureus* (MuH MRSA). *Diagn. Microbiol. Infect. Dis.* **82**, 278-283 (2015).
998 This paper highlights multiple efflux gene carriage in clinical isolates of *S. aureus*. It presents
999 a complex picture with a majority of isolates harboring 2 or more efflux pump gene
1000 determinants. Report of isolates harboring multiple efflux genes are now more common.
1001
- 1002 147. Hijazi, K. et al. Susceptibility to chlorhexidine amongst multidrug-resistant clinical
1003 isolates of *Staphylococcus epidermidis* from bloodstream infections. *Int. J. Antimicrob.*
1004 *Agents* **48**, 86-90 (2016).
- 1005 148. Conceição, T., Coelho, C., de Lencastre, H., Aires-de-Sousa, M. High prevalence of
1006 biocide resistance determinants in *Staphylococcus aureus* isolates from three African
1007 countries. *Antimicrob. Agents Chemother.* **60**, 678-681 (2015).
- 1008 149. Wand, M.E. et al. Characterization of pre-antibiotic era *Klebsiella pneumoniae* isolates
1009 with respect to antibiotic/disinfectant susceptibility and virulence in *Galleria mellonella*.
1010 *Antimicrob. Agents Chemother.* **59**, 3966-3972 (2015).
- 1011 150. Lin, F. et al. Molecular characterization of reduced susceptibility to biocides in clinical
1012 isolates of *Acinetobacter baumannii*. *Front. Microbiol.* **8**, 1836 (2017).
- 1013 151. Elkhatib, W.F., Khalil, M.A.F. & Ashour, H.M. Integrons and antiseptic resistance genes
1014 mediate resistance of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates
1015 from intensive care unit patients with wound infections. *Curr. Mol. Med.* **19**, 286-293
1016 (2019).
- 1017 152. Goodarzi, R., Yousefimashouf, R., Taheri, M., Nouri, F & Asghari, B. Susceptibility to
1018 biocides and the prevalence of biocides resistance genes in clinical multidrug-resistant

- 1019 *Pseudomonas aeruginosa* isolates from Hamadan, Iran. *Mol. Biol. Reports* **48**, 5275-
1020 5281 (2021).
- 1021 153. Namaki, M. et al. Prevalence of resistance genes to biocides in antibiotic-resistant
1022 *Pseudomonas aeruginosa* clinical isolates. *Mol. Biol. Reports* **49**, 2149-2155 (2022).
- 1023 154. Boutarfi, Z. et al. Biocide tolerance and antibiotic resistance of *Enterobacter* spp.
1024 isolated from an Algerian hospital environment. *J. Global Antimicrob. Res.* **18**, 291-297
1025 (2019).
- 1026 155. Medardus, J.J. et al. In-feed use of heavy metal micronutrients in U.S. swine production
1027 systems and its role in persistence of multidrug-resistant *Salmonellae*. *Appl. Environ.*
1028 *Microbiol.* **80**, 2317–2325 (2014).
- 1029 156. Correa, J.E., De Paulis, A., Predari, S., Sordelli, D.O. & Jeric, P.E. First report of *qacG*,
1030 *qacH* and *qacJ* genes in *Staphylococcus haemolyticus* human clinical isolates. *J.*
1031 *Antimicrob. Chemother.* **62**, 956-960 (2008).
- 1032 157. Jiang, X. et al. Examination of quaternary ammonium compound resistance in *Proteus*
1033 *mirabilis* isolated from cooked meat products in China. *Front. Microbiol.* **8**, 2417 (2017).
- 1034 158. Jiang, X. et al. Characterization and horizontal transfer of *qacH*-associated class 1
1035 integrons in *Escherichia coli* isolated from retail meats. *Int. J. Food Microbiol.* **258**, 12-
1036 17 (2017).
- 1037 159. Wales, A.D. & Davies, R.H. Co-selection of resistance to antibiotics, biocides and heavy
1038 metals, and its relevance to foodborne pathogens. *Antibiotics* **4**, 567-604 (2015).
- 1039 160. Pal, C. et al. Chapter seven- Metal resistance and its association with antibiotic
1040 resistance. *Adv. Microb. Physiol.* **70**, 261-313 (2017).
- 1041 161. Sidhu, M.S., Heir, E., Leegaard, T., Wiger, K. & Holck, A. Frequency of disinfectant
1042 resistance genes and genetic linkage with beta-lactamase transposon Tn552 among
1043 clinical staphylococci. *Antimicrob. Agents Chemother.* **46**, 2797-2803 (2002).
- 1044 162. Harrison, K.R., Kappell, A.D. & McNamara, P.J. Benzalkonium chloride alters
1045 phenotypic and genotypic antibiotic resistance profiles in a source water used for
1046 drinking water treatment. *Environ. Poll.* **257**, 113472 (2020).
- 1047 163. Siani, H. & Maillard, J.-Y. Best practice in healthcare environment decontamination. *Eur.*
1048 *J. Infect. Control Infect. Dis.* **34**, 1-11 (2015).
- 1049 164. Van Asselt, A.J. & te Giffel, M.C. Pathogen resistance to sanitisers. Introduction. In
1050 Handbook of hygiene control in the food industry (eds. Lelieveld, H.L.M, Mostert, M.A.
1051 & Holah, J.) 69-92 (Woodhead Publishing, 2005)
- 1052 165. Maillard, J.-Y. et al. Reducing antibiotic prescribing and addressing the global problem
1053 of antibiotic resistance by targeted hygiene in the home and everyday life settings: A
1054 position paper. *Am. J. Infect. Control.* **48**, 1090-1099 (2020).

- 1055 166. Wellcome Trust. The Global response to Amr. Momentum, success, and critical gaps.
1056 [https://cms.wellcome.org/sites/default/files/2020-11/wellcome-global-response-amr-
1058 report.pdf](https://cms.wellcome.org/sites/default/files/2020-11/wellcome-global-response-amr-
1057 report.pdf) (2020).
1059 167. O’Neil, J. Tackling Drug-resistant Infections Globally; Final report and
1060 recommendations; [https://amr-
1062 review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf](https://amr-
1061 review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf), accessed
1063 11/01/22 (2006).

1063 **Highlighted references**

1064 Sentences highlighting key references added underneath selected references.

1065

1066 **Acknowledgements**

1067 The authors wish to thank the editor for the advice received and the thorough text editing.

1068

1069 **Author contributions**

1070 The authors contributed equally to all aspects of the manuscript.

1071

1072 **Peer review information**

1073 *Nature Reviews Microbiology* thanks Anabela Borges, Ilias Tagkopoulos, Manuel Simões, and
1074 the other, anonymous, reviewers for their contribution to the peer review of this work.

1075

1076 **Competing interests**

1077 J.Y. Maillard is the Director of Biocide Consult Ltd. M. P. declares no competing interests.

1078

1079 **Supplementary information**

1080 Supplementary information is available for this paper at [https://doi.org/10.1038/s415XX-
1082 XXX-XXXX-X](https://doi.org/10.1038/s415XX-
1081 XXX-XXXX-X)

1083

1084 **Related links**

1085 **ECHA:** <https://echa.europa.eu/information-on-chemicals/biocidal-active-substances>

1086

1087 **ECHA, Biocidal Product Regulation:** [https://echa.europa.eu/regulations/biocidal-products-
1089 regulation/legislation](https://echa.europa.eu/regulations/biocidal-products-
1088 regulation/legislation)

1089

1090

1091

1092 **Display items**

1093

1094 **Table 1.** Mayor types of biocides and their mechanisms of action

1095

1096

| Types | Mechanism of action | Examples of chemistry | Application and areas of use |
|---|---|--|---|
| Highly reactive biocides - strong interactions through chemical or ionic binding | | | |
| Alkylating agents | Reacts with amino acids to form cross links and fix proteins. | Glutaraldehyde, formaldehyde, ortho-phthalaldehyde (OPA) | Disinfection of surfaces, materials, equipment Disinfection of materials and surfaces associated with the housing or transportation of animals |
| Oxidising agents | Oxidation of macromolecules (proteins, lipids and nucleotides), whilst causing non-specific damage to the cytoplasmic membrane | Sodium hypochlorite, peracetic acid, hydrogen peroxide, ethylene oxide | Disinfection of surfaces, materials, equipment Disinfection of materials and surfaces associated with the housing or transportation of animals. Disinfection of drinking water |
| | | Povidone-iodine | Disinfection of skin, scalps, surfaces, materials, equipment |
| Less reactive biocides - weak physical interaction | | | |
| Cationics | Positively charged, hydrophilic region interacts with negatively charged cell surface. Hydrophobic region partitions into membrane, disrupting intermolecular bonds and leading to loss of intracellular contents | Quaternary ammonium compounds (for example, benzalkonium chloride) Biguanides (for example, chlorhexidine, polyhexamethylene biguanide) Diamines, amine oxides | Disinfection of skin, scalps Disinfection of surfaces, materials, equipment Incorporated in textiles, tissues, mask, producing treated articles with self-disinfecting properties Antisepsis of skin, scalps. Disinfection of surfaces, materials, equipment, swimming pools. Disinfection of surfaces, materials, equipment |
| Phenolics | Protonophore which targets the cytoplasmic membrane, causing loss of membrane potential. At low concentrations, triclosan inhibits fatty acid synthesis | Triclosan | Disinfection of surfaces, materials, equipment Incorporated in textiles, tissues, mask, producing treated articles with disinfecting properties |
| Alcohols | Permeabilization of the cytoplasmic membrane; denaturation of proteins; dehydration of exposed bacteria | Ethyl alcohol (ethanol), isopropyl alcohol | Disinfection of skin, scalps Disinfection of surfaces, materials, equipment |
| Weak organic acids | Uncoupling of proton motive force; Acidification of bacterial cytoplasm, leading to inhibition of | Citric acid, benzoic acid | Disinfection of skin, scalps Disinfection of surfaces, materials, equipment |

| | | | |
|--------------------|--|--|--|
| | enzyme activity and biosynthesis whilst exerting osmotic stress | | |
| Metal ions | Redox active. Interacts with thiol groups and generates reactive oxygen species which damages macromolecules | Silver, copper | Antimicrobial surfaces, textiles, wound dressings |
| Antimicrobial dyes | Intercalation with DNA. Production of singlet oxygen (photosensitisers) | Methylene blue, toluidine blue, crystal violet | Wound dressings, photodynamic therapy (photosensitisers) |

1097 Table information based partly on^{21,27}

1098

1099

1100 **Table 2.** Extrinsic factors affecting the performance of biocides

1101

| | | |
|---------------------|---|--|
| Biocide properties | Mechanism of action | Spectrum of activity determined by chemistry underlying biocide-microbe interaction |
| | Use concentration | Concentration correlates with speed of effect |
| | Formulation and product composition | Excipients, co-actives and pH may affect biocide reactivity, interaction with bacterial cells (for example, EDTA destabilisation of outer membrane), drying time (formulation to wipe ratio) and surface wettability (surfactants) |
| Application factors | Contact time | Level of inactivation partially determined by time (disinfection kinetic) |
| | Presence of organic soils (Has the surface been cleaned?) | Organic matter may react with biocides and reduce performance |
| | Surface type | Performance may be affected by target surface (for example, polyvinyl chloride (PVC) versus stainless steel) |
| | Environmental temperature | Increased temperature increases rate of reaction |
| | Method of delivery (for example, vapourisation, spraying, wiping) | Efficacy of a biocide will change if it is in a liquid or gas form. The method of delivery will also impact on the overall efficacy of the formulation. |
| | Interactions between biocide and applicator | Some biocides may interact with applicator (for example, wipe material), reducing effective concentration |
| | Concentration upon subsequent dilution and abrasion | Reduction in concentration during use may reduce biocidal efficacy |
| Target organism | Endospores | Metabolically inactive structures of <i>Bacillus</i> spp. and <i>Clostridioides</i> spp. highly tolerate biocide exposure (FIG. 3) |
| | Bacterial type (for example, mycobacteria, Gram-negative species) | Intrinsic factors may affect resistance to specific biocides (for example, outer membrane and quaternary ammonium compounds (QACs)) |
| | Metabolic activity | Reduced metabolism associated with decreased susceptibility |

| | |
|-------------------|---|
| Lifestyle (BOX 1) | Microbial communities (biofilms) exhibit reduced susceptibility to antimicrobials |
|-------------------|---|

1102 EDTA, ethylenediaminetetraacetic acid.

1103

1104

1105 **Table 3.** Mechanisms of acquired biocide resistance and biocide-induced cross-resistance to antibiotics.

1106

| General mechanism | Organism | Biocide (test concentration) | Change in biocide susceptibility | Antibiotic resistance | Specific mechanism | Reference |
|--------------------------|----------------------------|---|---|--|--|-----------|
| Efflux | | | | | | |
| | Mixed waterborne community | Copper (8-500 mg/L) | N/A (environmental isolates only) | Clarithromycin; Tetracycline | CusA, CusB CusS, CutE | 113 |
| | <i>A. baumannii</i> | Triclosan (128 mg/L) | 2- to 32-fold increase in MIC | Trimethoprim | FabI, AdellJK | 114 |
| | <i>P. aeruginosa</i> | Benzalkonium chloride (BZC) (12.5 mg/L) | 12-fold increase in MIC | Ampicillin; Cefotaxime; Ceftazidime | MexAB-OprM; MecCD-OprJ | 115 |
| | <i>Campylobacter spp.</i> | BZC; Chlorhexidine; Cetylpyridinium chloride | 2- to 4-fold increase in MIC | Erythromycin; Ciprofloxacin | Not established (confirmed with efflux inhibitors) | 116 |
| | <i>P. aeruginosa</i> | Sodium hypochlorite (100 mg/L) | circa 2.5-fold increase in MIC | Ampicillin; Tetracycline; Chloramphenicol Kanamycin | MuxABC-OpmB* | 117 |
| Porins | | | | | | |
| | <i>M. chelonae</i> | Glutaraldehyde (0.2-2%) | >6 log ₁₀ survival of resistant strain in 2% glutaraldehyde | Rifampicin, Vancomycin, Clarithromycin, Erythromycin | Msp | 80 |
| | <i>E. coli</i> | Chlorophene (0.5-2.49 mM) Povidone-iodine (67-111 µg/ml) | Increased growth in 2- to 5-fold higher concentrations of biocide after 500 generations | Ampicillin; Chloramphenicol; Norfloxacin | OmpR; EnvZ | 82 |
| Metabolic changes | | | | | | |
| | <i>E. coli</i> | Hydrogen peroxide (200 µM) | Increased growth in circa 2-fold higher concentration after 500 generations | Ampicillin; Chloramphenicol | RNA polymerase (<i>rpo</i>) | 82 |

| | | | | | |
|-------------------------------|---------------------------|------------------------------|-----------------|--------------------------------------|-----|
| <i>M. smegmatis</i> | Triclosan (0.8-1.6 mg/ml) | 4- to 6-fold increase in MIC | Isoniazid | Lipid metabolism (InhA) | 112 |
| <i>Listeria monocytogenes</i> | Triclosan (1-4 µg/ml) | No change in MIC | Aminoglycosides | Heme metabolism (<i>hemH/hemA</i>) | 111 |

Modification of surface charge

| | | | | | |
|-------------------------------------|--------------------|--|---|-------------|-----|
| <i>P. aeruginosa</i> | BZC (50-1600 mg/L) | 7 to 25-fold increase in MIC | Polymyxin B | <i>pmrB</i> | 67 |
| Extracellular metal-binding protein | | | | | |
| <i>Klebsiella pneumoniae</i> | Silver (≤64 µM) | N/A (clinical isolates only); resistance to silver based on literature values. | Beta lactams, fluoroquinolones, aminoglycosides (plasmid-encoded) | SilE | 118 |

1107 *Induction of SOS response and antioxidant enzymes also noted

1108 N/A, not applicable; MIC, minimal inhibitory concentration.

1109

1110

1111 **Figure 1.** Susceptibility of microorganisms to biocides. Biocide efficacy depends partly on the
1112 type of microorganisms being targeted. High, intermediate and low refer to level of disinfection
1113 required to render a contaminated surface safe and depends on the expected microbial
1114 contaminant. The least susceptible organisms, such as bacterial endospores, require high
1115 level disinfection delivered by reactive oxidising and alkylating agents. Prions are the agents
1116 responsible for mad cow disease and new variant Creutzfeldt-Jakob disease. Their proteinic
1117 nature makes them less susceptible to conventional high-level disinfectants. Some
1118 microorganism types including enveloped viruses, and to some extent vegetative Gram-
1119 positive bacteria, are usually more susceptible to biocides and will be killed by quaternary
1120 ammonium compound (QAC) formulations, biguanides, antimicrobial dyes and phenolics.
1121 Enveloped viruses are particularly susceptible to membrane active agents including both
1122 biocides and detergents. Multidrug antibiotic resistant clinical isolates are not necessarily less
1123 susceptible to biocides when used at their in-use concentration, though some isolates can
1124 exhibit increased tolerance to dilute solutions of biocide, depending on the mechanism of
1125 resistance. Environmental isolates, however, can be less susceptible to biocides at their in-
1126 use concentration. Vegetative referred to bacteria that can actively divide and cause an
1127 infection as opposed to bacterial endospores which are a form of bacterial survival and are
1128 dormant (see main text). ClO₂, chlorine dioxide; IPA, isopropyl alcohol; EtOH, ethyl alcohol.

1129
1130 **Figure 2.** Mechanisms of action of disinfectants and antiseptics. The mechanisms of action of
1131 biocides depends on the main bacterial structures targeted^{23,27}. On the left, major bacterial
1132 targets of biocides. On the right, the inactivation of bacterial cells by biocides is a time and
1133 concentration-dependent process which follows a series of reversible and irreversible events.
1134 Reversible events include initial release of intracellular potassium (a), which causes a
1135 depletion of membrane potential and loss of protonmotive force (PMF) necessary for ATP
1136 biosynthesis (b). This leads to an arrest of active transport (c), normal metabolic processes
1137 (d) and replication (e). Continued exposure to the biocide eventually leads to irreversible
1138 damage, including changes to cytosolic pH (f), which cascades into disruption of enzymatic
1139 function and coagulation of intracellular material (g). If the cytoplasmic membrane becomes
1140 significantly damaged, cytoplasmic constituents including proteins, nucleotides, pentoses and
1141 other ions may be lost from the cell (h). Whilst not considered a biocide,
1142 ethylenediaminetetraacetic acid (EDTA) disrupts the outer membrane of Gram-negative
1143 bacteria, potentiating biocidal effects.
1144 QAC, quaternary ammonium compound; PAA, peracetic acid, H₂O₂, hydrogen peroxide;
1145 PO₄³⁻, phosphate; K⁺, potassium ion.

1146
1147

1148 **Figure 3.** Intrinsic factors governing microbial resistance and tolerance to biocides. a) in a
1149 vegetative bacterium, the outer surface of some species may act as an impermeable barrier,
1150 preventing biocide diffusion into the cytoplasmic space. Penetration of biocides can be
1151 moderated by the density and substrate specificity of porins. In some cases, biocide–cell
1152 surface interactions are modulated by surface properties, such as charge and fatty acid
1153 composition. Pigments, including melanins and carotenoids, can quench the activity of both
1154 cationic and oxidising biocides. Biocides that reach the cytoplasmic membrane, periplasm or
1155 cytoplasm may be actively exported from the cell by efflux pumps, reducing their effective
1156 concentration. b) In the case of endospores, damage to nucleic acids can be substantially
1157 reduced by a variety of DNA protection mechanisms. c) in sessile biofilms, extracellular
1158 polymeric substances may substantially interfere with microbicidal activity, whilst metabolic
1159 changes and enhanced SOS response induction protects against insults; cell–cell
1160 communication and horizontal gene transfer are enhanced within biofilm communities. Non-
1161 specific mechanisms of resistance may confer cross-resistance to a range of antimicrobial
1162 agents, including antibiotics. SASPs, small acid-soluble proteins; VBNC, viable but non-
1163 culturable, DAP–CA²⁺, Dipicolinic acid bound to calcium.
1164
1165